Literature DB >> 1630856

Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age.

N Kacet1, M Roussel-Delvallez, C Gremillet, J P Dubos, L Storme, P Lequien.   

Abstract

The pharmacokinetics of piperacillin after a single 75-mg/kg intravenous injection as analyzed in 28 neonates with gestational ages of 29 to 40 weeks (A = 29 to 31 weeks, B = 33 to 35 weeks, C = 38 to 42 weeks) and birth weights of 860 to 3900 g during 35 courses. Serum concentrations of piperacillin were determined by high pressure liquid chromatography. A one compartment open model characterized the disposition of piperacillin. Twenty courses were given between Day 3 and Day 5 of life. The elimination half-life and total body clearance were related to gestational age. Differences were significant between Groups A and B and Group C for half-life (4.3 +/- 1.9 and 3.35 +/- 0.75 vs. 2.47 +/- 0.72 hours) and for clearance (1.68 +/- 0.6 and 1.8 +/- 0.4 vs. 2.46 +/- 0.36 ml/min/kg). Volumes of distribution were similar in the 3 groups, from 516 +/- 108 to 633 +/- 226 ml/kg. Fourteen courses were given from Day 9 to Day 11 of life. The same differences were observed between Groups A and B and Group C. Elimination half-life was significantly reduced with simultaneous increase of the total body clearance. In clinical practice, 75-mg/kg intravenous injections every 12 hours during the first week of life and every 8 hours in the second week provide appropriate concentrations in infants of less than 36 weeks gestational age. In full term newborns the 75-mg dosage is appropriate but the number of injections must be increased to 3/24 h for the first week and 4 times daily thereafter.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630856     DOI: 10.1097/00006454-199205000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of penicillins in the neonate: a review of the literature.

Authors:  G M Pacifici; J Labatia; H Mulla; I Choonara
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

3.  Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Stéphanie Leroux; Mark A Turner; Chantal Barin-Le Guellec; Helen Hill; Johannes N van den Anker; Gregory L Kearns; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

4.  Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.

Authors:  Yewei Chen; Jinmiao Lu; Min Dong; Dan Wu; Yiqing Zhu; Qin Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2016-09-19       Impact factor: 2.953

Review 5.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin.

Authors:  J N van den Anker; W C Hop; R C Schoemaker; B J van der Heijden; H J Neijens; R de Groot
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 7.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants.

Authors:  Michael Cohen-Wolkowiez; Nicole R White; Arlene Bridges; Daniel K Benjamin; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-22       Impact factor: 3.205

9.  Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants.

Authors:  Sara Salerno; Christoph P Hornik; Michael Cohen-Wolkowiez; P Brian Smith; Lawrence C Ku; Matthew S Kelly; Reese Clark; Daniel Gonzalez
Journal:  Pediatr Infect Dis J       Date:  2017-09       Impact factor: 3.806

10.  Population pharmacokinetics of piperacillin using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniel K Benjamin; Ashley Ross; Laura P James; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniele Ouellet
Journal:  Ther Drug Monit       Date:  2012-06       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.